A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

Abstract Background Escalating healthcare costs are necessitating the practice of value-based oncology. It is crucial to critically evaluate the economic impact of influential but expensive therapies such as immune checkpoint inhibitors (ICIs). To date, no systematic assessment of the cost-effective...

Full description

Bibliographic Details
Main Authors: Vivek Verma, Tanja Sprave, Waqar Haque, Charles B. Simone, Joe Y. Chang, James W. Welsh, Charles R. Thomas
Format: Article
Language:English
Published: BMJ Publishing Group 2018-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40425-018-0442-7